Detail
| LncRNA Name | FEZF1-AS1 |
| Synonyms | NR_036484 |
| Region | GRCh38_7:122303658-122310077 Sequence |
| Ensembl | ENSG00000230316 |
| RefSeq | NR_036484 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | pancreatic ductal adenocarcinoma |
| ICD-0-3 | C25.3 M8500/3 |
| Methods | Microarray, qRT-PCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP |
| Sample | PDAC tissues, PC cell lines (PANC-1, Capan-2, MIAPaCa-2, SW1990, and BxPC-3) |
| Expression Pattern | up-regulated |
| Function Description | A novel lncRNA FEZF1-AS1 and its sense-cognate gene ZNF312B were found to be highly expressed in human PDAC tissues and cell lines, which is associated with disease progression and predicts clinical outcome in PDAC patients.FEZF1-AS1 may act as an endogenous sponge by competing for miR-107, thereby modulating the derepression of ZNF312B. Downregulation of FEZF1-AS1 or ZNF312B significantly inhibited proliferation, colony formation, migration, and invasion of PDAC cells in vitro, whereas the miR-107 inhibitor abrogated the effect of dow-regulation of FEZF1-AS1 or ZNF312B in reducing oncogenic capacities of PDAC cells.In addition, FEZF1-AS1/miR-107/ZNF312B axis-induced promotion of PDAC cells proliferation appeared to be mediated by modulation of the apoptosis and the G1-S checkpoint. |
| Pubmed ID | 29348628 |
| Year | 2018 |
| Title | FEZF1-AS1/miR-107/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma. |
| External Links |
| Links for FEZF1-AS1 | GenBank HGNC lncrnadb Noncode |
| Links for pancreatic ductal adenocarcinoma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.